Biochemical Engineering
Scancell Selects Cobra to make plasmids for COVID-19 vaccine phase I trial
2nd October 2020
Cobra Biologics, a CDMO and part of Cognate BioServices, and Scancell Holdings have entered into a collaboration for Cobra to manufacture Scancell’s COVID-19 vaccine. The agreement covers GMP production of plasmid DNA needed to generate the DNA vaccine, against SARS-CoV-2, for use in a Phase 1 clinical trial in 2021 (COVIDITY). The project is funded by an Innovate UK grant awarded to the consortium between Scancell, the University of Nottingham, and Trent University, as previously announced in August. Source: Genetic Engineering News 2/10/2020
Back to group news